GlassScriptPhysician profile
Lina Kennedy
NPI 1467719260
$3,052.15
in general payments reported to CMS, 2019-2025
24 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $217 · 2021: $186 · 2022: $231 · 2023: $292 · 2024: $282 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $366.08 | 2019-2020 | |
| Lilly USA, LLC | $336.41 | 2019-2025 | Taltz, Ebglyss |
| Allergan, INC. | $297.20 | 2019-2022 | |
| Abbvie INC. | $270.21 | 2019-2025 | |
| Pfizer INC. | $239.56 | 2019-2020 | |
| Celgene Corporation | $221.20 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $197.67 | 2022-2025 | Clear+Brilliant |
| Galderma Laboratories, L.P. | $176.03 | 2019-2025 | |
| Ucb, INC. | $161.46 | 2019-2024 | Bimzelx |
| Incyte Corporation | $157.85 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $124.56 | 2025 | Libtayo |
| Genzyme Corporation | $86.84 | 2019-2025 | |
| Genentech USA, INC. | $76.81 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $53.34 | 2019 | |
| Mayne Pharma Commercial LLC | $44.02 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $43.04 | 2019 | |
| Biofrontera INC. | $43.02 | 2019 | |
| Prugen, INC. Pharmaceuticals | $32.59 | 2019 | |
| Aclaris Therapeutics, INC. | $25.40 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.85 | 2019 | |
| Amgen INC. | $23.11 | 2024 | Otezla |
| Merz North America, INC. | $18.24 | 2020 | |
| Vyne Pharmaceuticals INC. | $17.36 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.